Back to Stocks

CTMX

CytomX Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

CytomX Therapeutics has successfully transitioned into a lean, clinical-stage execution machine, evidenced by a strategic restructuring that reduced its workforce by 40% and a massive $234.2 million equity raise in March 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite a pristine cash balance, CytomX is grappling with a collapsing revenue base and a persistent cash-burn problem.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CTMX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical inflection point, having traded its diversified collaboration model for a high-conviction bet on Varseta-M. The successful March 2026 financing has removed the immediate 'going concern' risk, but it has come at the cost of significant equity dilution. The core tension for investors now lies in the gap between the company's lean operational narrative and the reality of its accelerating operating cash burn. Ultimately, the stock's trajectory is now binary and tied exclusively to the clinical success of Varseta-M. While the Phase 1 data is encouraging, the loss of strategic partners like BMS and Amgen removes the external validation that typically supports biotech valuations. The coming 12 months, featuring FDA alignment and the launch of combination studies, will determine if CytomX is a disciplined clinical operator or simply a cash-burning entity with a dwindling set of options.

Selected Quarter

Core Takeaway

CytomX has traded its collaboration-heavy revenue model for a single-asset clinical focus, backed by a $346.7M cash cushion.

Investor Lens

The trade-off is between the high-reward potential of a first-in-class ADC and the high risk of a single-asset pipeline with no partner revenue.

Watch Next

FDA alignment on the registrational trial design for Varseta-M monotherapy in 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.17Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%
bullishMay 7

Successfully raised $234.2 million in March 2026 to extend cash runway.

capital raise
90%
bearishMay 7

Revenue dropped 79% year-over-year due to termination of major collaborations.

earnings miss
80%
bearishMay 7

Operating cash burn increased to $25.5 million despite a 40% workforce reduction.

margin compression
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical inflection point, having traded its diversified collaboration model for a high-conviction bet on Varseta-M. The successful March 2026 financing has removed the immediate 'going concern' risk, but it has come at the cost of significant equity dilution. The core tension for investors now lies in the gap between the company's lean operational narrative and the reality of its accelerating operating cash burn. Ultimately, the stock's trajectory is now binary and tied exclusively to the clinical success of Varseta-M. While the Phase 1 data is encouraging, the loss of strategic partners like BMS and Amgen removes the external validation that typically supports biotech valuations. The coming 12 months, featuring FDA alignment and the launch of combination studies, will determine if CytomX is a disciplined clinical operator or simply a cash-burning entity with a dwindling set of options.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.